Weather

89°F8:19 PM

Health

1 read

Innovadora terapia SAINT ofrece nueva esperanza para combatir la depresión resistente

KVIA•Friday, January 16, 2026 at 2:05 AM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

Valerie Zeko, una mujer de 57 años, ha luchado contra la depresión resistente al tratamiento durante casi tres décadas. En 2023, se unió a un ensayo clínico en la Universidad de Stanford que probaba una nueva terapia llamada SAINT, diseñada para enviar pulsos magnéticos a la corteza prefrontal del cerebro. Tras solo una semana de tratamiento, Zeko experimentó mejoras significativas en su calidad de vida, disfrutando actividades que antes le resultaban imposibles. El estudio reveló que el 50% de los participantes en el grupo de tratamiento alcanzaron la remisión, en comparación con solo el 21% en el grupo placebo. Este avance en la terapia de salud mental representa un cambio potencial en el tratamiento de la depresión resistente, ofreciendo esperanza a quienes no han encontrado alivio con métodos tradicionales.

Key Details: • El ensayo clínico se realizó en el Brain Stimulation Lab de la Universidad de Stanford. • SAINT está diseñado para tratar la depresión resistente al tratamiento mediante pulsos magnéticos. • El 50% de los participantes en el grupo de tratamiento logró la remisión tras un mes. • Los resultados fueron publicados en la revista World Psychiatry.

investigacion salud-mental depresion terapia ensayo-clinico

People & Organizations

San FranciscoValerie ZekoDr. Brandon BentzleyDr. Ian KratterDr. Nolan WilliamsMagnus MedicalUniversidad de Stanford

Related Articles

El Paso Center for Diabetes to Host Overnight Camps for Teens in 2026

The El Paso Center for Diabetes is set to revive its youth overnight camps, with the first camp scheduled for April 10-12, 2026. This camp will cater to teenagers aged 12 to 17 and will take place in Angus, New Mexico, approximately 16 miles from El Paso. These camps aim to provide education and support for young individuals managing diabetes, fostering a sense of community and empowerment. Parents and guardians should mark their calendars for this opportunity to enhance their children's health and social skills.

Novo Nordisk Cuts Prices of Ozempic and Wegovy by 50% Starting 2027

Novo Nordisk has announced a significant reduction in the list prices of its popular diabetes and weight loss medications, Ozempic, Wegovy, and Rybelsus, by up to 50% starting in 2027. The current list price for Wegovy is $1,349, while Ozempic and Rybelsus are priced at $1,028. This price cut aims to improve accessibility for patients, particularly those with high deductibles or co-insurance plans. The move comes as Novo Nordisk competes with Eli Lilly, which has gained market share in the obesity medication sector. Despite the list price reductions, self-pay prices will remain unaffected. The company recently reported disappointing trial results for its next-generation obesity drug, contributing to a decline in its stock price.

Trump's Glyphosate Order Sparks Controversy Among Health Advocates in El Paso

An executive order by President Trump has declared glyphosate, a widely used herbicide, essential for national security and economic stability, which has drawn ire from health advocates, particularly those associated with the 'Make America Healthy Again' (MAHA) movement. The order emphasizes the need for a domestic supply of glyphosate, despite ongoing health concerns about its potential carcinogenic effects. Critics, including Zen Honeycutt of Moms Across America, argue that this move may protect Monsanto from lawsuits related to glyphosate's health risks. The order coincides with Bayer's proposed $7.25 billion settlement over cancer claims linked to Roundup, the product containing glyphosate. Health experts warn of the herbicide's risks, especially to children, as studies indicate increased cancer risks associated with exposure.

How Technology is Enhancing Patient Engagement in Healthcare

Recent advancements in technology are significantly improving the way patients interact with their healthcare providers. Tools like home blood pressure monitors, glucometers, and smartwatches allow patients to collect vital health data, which can be shared during appointments to enhance treatment plans. For example, accurate blood pressure readings require validated devices and specific techniques to ensure reliability. This shift towards patient-generated data is transforming healthcare from a reactive to a proactive model, enabling more personalized care. However, while technology plays a crucial role, it is essential to maintain the personal connection during in-person visits.